Carboplatin Hypersensitivity Reactions: A Single Institution Experience

References

• Boils G, Scarfone G, Polverino G et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004; 22: 686–690.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and pacli-taxel in patients with optimally resected stage III ovarian can-cer: a Gynecologic Oncology Group study. J Clin Oncol 2004; 21: 3194–3200.
   Web of Science ®Google Scholar
• International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxoru-bicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505–515.
   PubMedGoogle Scholar
• Dizon DS, Dupont J, Anderson S et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2003; 91: 584–590.
   Google Scholar
• Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conven-tional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON 4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099–2106.
   Google Scholar
• Ratain MJ, Tempero M, Skosey C. Outline of Oncology Therapeutics W.B. Saunders Company, 2001.
   Google Scholar
• Markman M, Kennedy A, Webster K et al. Clinical fea-tures of Hypersensitivity Reactions to Carboplatin. J Clin Oncol 1999; 17: 1141–1145.
   Web of Science ®Google Scholar
• Weidmann B, Mulleneisen N, Bojko P et al. Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer 1994; 8: 2218–2222.
   Google Scholar
• Schiavetti A, Varasso G, Maurizi P et al. Hypersensitivity to carboplatin in children. Med Pediatr Oncol 1999; 32: 183–185.
   PubMedGoogle Scholar
• Robinson JB, Singh D, Bodurka-Bevers DC et al. Hypersensitivity reactions and the utility of oral and intra-venous desensitization in patients with gynecologic malignan-cies. Gynecol Oncol 2001; 82: 550–558.
   PubMed Web of Science ®Google Scholar
• Broome CB, Schiff RI, Friedman HS. Successful desen-sitization to carboplatin in patients with systemic hypersensitiv-ity reactions. Med Pediatr Oncol 1996; 26: 105–10.
   PubMedGoogle Scholar
• Sims-Mc Callum RP. Outpatient carboplatin desensitiza-tion in a pediatric patient with bilateral optic glioma. Ann Pharmacother 2000; 34: 477–478.
   PubMed Web of Science ®Google Scholar
• Kook H, Kim KM, Choi SH et al. Life threatening car-boplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitiza-tion. Bone Marrow Transplantation 1998; 21: 727–729.
   PubMed Web of Science ®Google Scholar
• Bunn PA, Shepherd FA, Sandler A et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003; 41: 5175–5186.
   Google Scholar
• Freedman S, Krupey J. Respiratory allergy caused by platinum salts. J Allergy 1968; 42: 233–237.
   Google Scholar
• Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53: 121–122.
   PubMed Web of Science ®Google Scholar
• Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84: 378–382.
   PubMed Web of Science ®Google Scholar
• Markman M, Zanotti K, Kulp B, Peterson G, Markman M. Relationship between a history of systemic allergic reac-tions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 2003; 89: 514–516.
   PubMed Web of Science ®Google Scholar
• Zanotti KM, Rybicki LA, Kennedy AW et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19: 3126–3129.
   PubMed Web of Science ®Google Scholar
• Markman M, Zanotti K, Peterson G et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21: 4611–4614.
   Google Scholar
• Yu Dy, Dahl CV, Shames RS et al. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol 2001; 23: 349–352.
   PubMed Web of Science ®Google Scholar
• Jones R, Ryan M, Friedlander M. Carboplatin hyper-sensitivity reactions: re-treatment with cisplatin desensitization. Gynecol Oncol 2003; 89: 112–115.
   PubMed Web of Science ®Google Scholar
• Libra M, Sorio R, Buonadonna A et al. Cisplatin may be a valid alternative approach in ovarian carcinoma with car-boplatin hypersensitivity. Report of three cases. Tumori 2003; 89: 311–313.
   Google Scholar
• Ottaiano A, Tambaro R, Greggi S. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res 2003; 23: 3465–3468.
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Pautier P, Lhomme C. Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to car-boplatin. J Clin Oncol 2002; 20: 353–354.
   PubMed Web of Science ®Google Scholar
• Tsavaris NB, Kosmas C. Risk of severe acute hyper-sensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemother Pharmacol 1998; 42: 509–511.
   PubMed Web of Science ®Google Scholar